Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Whole-Genome Sequencing Results From 30 Patients with Waldenstrom's Macroglobulinemia

Zachary Hunter, Lian Xu, Yangsheng Zhou, MD, Guang Yang, PhD, Xia Liu, MD, Yang Cao, MD, Christina Hanzis, Patricia Sheehy, NP, Robert Manning, Christopher J Patterson, Jason M Laramie, PhD, Donald A Skifter, PhD, Stephen E Lincoln, PhD, Steven P Treon, MD, PhD

Blood (2011) 118 (21): 434.

https://doi.org/10.1182/blood.V118.21.434.434

Published: 2011

Journal Articles

Whole Genome Sequencing Reveals a Widely Expressed Mutation (MYD88 L265P) with Oncogenic Activity in Waldenstrom's Macroglobulinemia

Steven P Treon, MD, PhD, Lian Xu, Yangsheng Zhou, MD, Xia Liu, MD, Guang Yang, PhD, Yang Cao, MD, Christina Hanzis, Patricia Sheehy, NP, Robert Manning, Christopher J Patterson, Jason M Laramie, PhD, Donald A Skifter, PhD, Stephen E Lincoln, PhD, Zachary Hunter

Blood (2011) 118 (21): 300.

https://doi.org/10.1182/blood.V118.21.300.300

Published: 2011

Journal Articles

Treatment with a Bortezomib-Containing Regimen Is Associated with Better Therapeutic Outcomes in Patients with Waldenstrom's Macroglobulinemia Who Have Familial Disease Predisposition

Steven P Treon, MD, PhD, Zachary Hunter, Christina Hanzis, Christina Tripsas, Leukothea Ioakimidis, Christopher Patterson, Robert Manning, Patricia Sheehy, NP, Barry Turnbull, PhD

Blood (2011) 118 (21): 1643.

https://doi.org/10.1182/blood.V118.21.1643.1643

Published: 2011

Journal Articles

The Rituximab and IVIG Related IgM Flare In Waldenstrom's Macroglobulinemia Is Associated with Monocytic Activation of Fcgriia Signaling, and Triggering of IL-6 Release by the PI3K/AKT and MAPK Pathways

Guang Yang, MD, Lian Xu, Zachary Hunter, Xia Liu, MD, Yang Cao, MD, Jingrui Jiang, Hsiuyi Tseng, Yangsheng Zhou, MD, Leukothea Ioakimidis, Christina Hanzis, Patricia Sheehy, NP, Christopher Patterson, Steven P. Treon, MD, PhD

Blood (2010) 116 (21): 2870.

https://doi.org/10.1182/blood.V116.21.2870.2870

Published: 2010

Journal Articles

The Anti-CD20 Monoclonal Antibody GA101 Displays More Robust Anti-Tumor Activity Versus Rituximab In Waldenstrom's Macroglobulinemia (WM)

Guang Yang, MD, Christina Hanzis, Sigitas Verselis, PhD, Lian Xu, Zachary Hunter, Leukothea Ioakimidis, Patricia Sheehy, NP, Christopher Patterson, Edward Fox, PhD, Steven P. Treon, MD, PhD

Blood (2010) 116 (21): 4904.

https://doi.org/10.1182/blood.V116.21.4904.4904

Published: 2010

Journal Articles

Bendamustine-Based Therapy Is Highly Active In Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

Steven P. Treon, MD, PhD, Christina Hanzis, Christina Trispsas, Leukothea Ioakimidis, Christopher Patterson, Robert Manning, Patricia Sheehy, NP

Blood (2010) 116 (21): 4700.

https://doi.org/10.1182/blood.V116.21.4700.4700

Published: 2010

Journal Articles

Associated Malignancies Among Patients and Kin with Waldenstrom's Macroglobulinemia

Christina Hanzis, Zachary Hunter, Robert Manning, Megan Lewicki, Philip Brodsky, Leukothea Ioakimidis, Christina Tripsas, Christopher Patterson, Patricia Sheehy, NP, Steven P. Treon, MD, PhD

Blood (2010) 116 (21): 4159.

https://doi.org/10.1182/blood.V116.21.4159.4159

Published: 2010

Journal Articles

Comprehensive Assessment of Cytokines and Chemokines In Patients with Waldenstrom's Macroglobulinemia Reveals a Distinct Profile with Pathobiological and Clinical Relevance

Megan Lewicki, Bryan Ciccarelli, Zachary Hunter, Philip Brodsky, Robert Manning, Christina Hanzis, Christopher Patterson, Patricia Sheehy, NP, Steven P. Treon, MD, PhD

Blood (2010) 116 (21): 1911.

https://doi.org/10.1182/blood.V116.21.1911.1911

Published: 2010

Journal Articles

IgA and IgG Hypogammaglobulinemia Does Not Predict for Recurrent Infection Risk and Persists Despite Therapeutic Response in Patients with Waldentrom's Macroglobulinemia.

Zachary Hunter, Robert Manning, Christina Hanzis, Bryan Ciccarelli, Thea Ioakimidis, MS, Christopher J Patterson, Megan Lewicki, Hsuiyi Tseng, Ping Gong, Xia Liu, MD, Yangsheng Zhou, MD, PhD, Guang Yang, PhD, Jenny Sun, MD, Lian Xu, Patricia Sheehy, NP, Massimo Morra, MD, Steven Treon, MD, PhD

Blood (2009) 114 (22): 1947.

https://doi.org/10.1182/blood.V114.22.1947.1947

Published: 2009

Journal Articles

Genome Wide Association Studies of Familial Waldenstrom's Macroglobulinemia (WM) Reveals a Loss of GSTM1 Is Common in Families with a History of B-Cell Disorders but Not in Those with a History Specific for WM.

Zachary Hunter, Christina Hanzis, Thea Ioakimidis, MS, Christopher J Patterson, Bryan Ciccarelli, Megan Lewicki, Robert Manning, Lian Xu, Xia Liu, Hsiuyi Tseng, Ping Gong, Jenny Sun, MD, Yangsheng Zhou, MD, PhD, Guang Yang, PhD, Patricia Sheehy, NP, Edward A. Fox, PhD, Steven Treon, MD, PhD

Blood (2009) 114 (22): 762.

https://doi.org/10.1182/blood.V114.22.762.762

Published: 2009

Journal Articles

The Inhibitory Receptor FcgRIIB Is Overexpressed, and Its Ligation by Anti- FcgRIIB Antibodies Suppresses IgM Production and Induces Apoptosis in Waldenstrom's Macroglobulinemia.

Guang Yang, PhD, Ping Gong, Lian Xu, Zachary Hunter, Jenny Sun, MD, Bryan Ciccarelli, Yangsheng Zhou, MD, PhD, Xia Liu, Hsiuyi Tseng, Yang Cao, Robert Manning, Megan Lewicki, Christina Hanzis, Thea Ioakimidis, MS, Patricia Sheehy, NP, Christopher J Patterson, Steven Treon, MD, PhD

Blood (2009) 114 (22): 3736.

https://doi.org/10.1182/blood.V114.22.3736.3736

Published: 2009

Journal Articles

Maintenance Rituximab Is Associated with Improved Progression Free and Overall Survival in Waldenstrom's Macroglobulinemia.

Steven P Treon, MD, PhD, Christina Hanzis, Robert Manning, Thea Ioakimidis, MS, Christopher J Patterson, Zachary Hunter, Barry Turnbull, PhD, Patricia Sheehy, NP

Blood (2009) 114 (22): 3750.

https://doi.org/10.1182/blood.V114.22.3750.3750

Published: 2009

Journal Articles

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

Blood (2009) 114 (22): 587.

https://doi.org/10.1182/blood.V114.22.587.587

Published: 2009

Journal Articles

Progression Free Survival Is Predicated by Categorical Response, and Supports the Attainment of VGPR/CR as An Objective for Long Term Disease Control in Waldenstrom's Macroglobulinemia.

Steven Treon, MD, PhD, Thea Ioakimidis, MS, Christina Hanzis, Robert Manning, Christopher J Patterson, Zachary Hunter, Patricia Sheehy, NP, Barry Turnbull, PhD

Blood (2009) 114 (22): 4993.

https://doi.org/10.1182/blood.V114.22.4993.4993

Published: 2009

Journal Articles

Gene Expression Profiling Distinguishes Waldenstrom's Macroglobulinemia Patients Presenting with Familial Disease, Advanced IPSS Prognostic Score, and Previous Treatment with Rituximab.

Zachary Hunter, Evdoxia Hatjiharissi, MD, Jenny Sun, MD, Yang Cao, Hsiuyi Tseng, Megan Lewicki, Lian Xu, Guang Yang, PhD, Yangsheng Zhou, MD, PhD, Xia Liu, Ping Gong, Christina Hanzis, Thea Ioakimidis, MS, Christopher J Patterson, Patricia Sheehy, NP, Bart Barlogie, MD, PhD, John D Shaughnessy, Jr, PhD, Steven Treon, MD, PhD

Blood (2009) 114 (22): 3930.

https://doi.org/10.1182/blood.V114.22.3930.3930

Published: 2009

Journal Articles

The IgM Flare Following Rituximab and IVIG Administration in Waldenstrom's Macroglobulinemia Is Related to IL-6 Production by Bystander Immune Cells, Possibly through Stimulation of the Fcgriia Receptor.

Guang Yang, PhD, Ping Gong, Thea Ioakimidis, MS, Lian Xu, Zachary Hunter, Jenny Sun, MD, Bryan Ciccarelli, Yangsheng Zhou, MD, PhD, Xia Liu, Hsiuyi Tseng, Yang Cao, Robert Manning, Megan Lewicki, Christina Hanzis, Patricia Sheehy, NP, Christopher J Patterson, Steven Treon, MD, PhD

Blood (2009) 114 (22): 761.

https://doi.org/10.1182/blood.V114.22.761.761

Published: 2009

Journal Articles

Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia.

Blood (2009) 114 (22): 4785.

https://doi.org/10.1182/blood.V114.22.4785.4785

Published: 2009

Journal Articles

Cholesterol Regulation and Statin Therapy in Patients with Waldenstrom's Macroglobulinemia.

Thea Ioakimidis, MS, Christopher J Patterson, Zachary Hunter, Jacob Soumerai, Robert Manning, Diane L. Warren, Irene Ghobrial, M.D., Patricia Sheehy, NP, Steven Treon, MD, PhD

Blood (2009) 114 (22): 4789.

https://doi.org/10.1182/blood.V114.22.4789.4789

Published: 2009

Journal Articles

Patients with Waldenstrom's Macroglobulinemia Are Often Hypoferremic That Is Refractory to Oral Iron Repletion and Responsive to Parental Iron Infusions, and Demonstrate Elevated Levels of Hepcidin.

Bryan Ciccarelli, Christopher J Patterson, Zachary Hunter, Christina Hanzis, Thea Ioakimidis, MS, Robert Manning, Guang Yang, PhD, Ping Gong, Lian Xu, Yangsheng Zhou, MD, PhD, Jenny Sun, MD, Xia Liu, Hsiuyi Tseng, Yang Cao, Patricia Sheehy, NP, Steven Treon, MD, PhD

Blood (2009) 114 (22): 2952.

https://doi.org/10.1182/blood.V114.22.2952.2952

Published: 2009

Journal Articles

Polymorphisms of FcγRIIA, FcγRIIB, and FcγRIIIA and Therapeutic Response to Rituximab Combination Therapy in Patients with Waldenstrom's Macroglobulinemia.

Guang Yang, PhD, Christina Hanzis, Ping Gong, Sigitas Verselis, PhD, Edward A. Fox, PhD, Lian Xu, Bryan Ciccarelli, Yangsheng Zhou, MD, PhD, Zachary Hunter, Jenny Sun, MD, Xia Liu, Hsiuyi Tseng, Yang Cao, Robert Manning, Megan Lewicki, Thea Ioakimidis, MS, Patricia Sheehy, NP, Christopher J Patterson, Steven Treon, MD, PhD

Blood (2009) 114 (22): 2949.

https://doi.org/10.1182/blood.V114.22.2949.2949

Published: 2009

NARROW

Whole-Genome Sequencing Results From 30 Patients with Waldenstrom's Macroglobulinemia

Whole Genome Sequencing Reveals a Widely Expressed Mutation (MYD88 L265P) with Oncogenic Activity in Waldenstrom's Macroglobulinemia

Treatment with a Bortezomib-Containing Regimen Is Associated with Better Therapeutic Outcomes in Patients with Waldenstrom's Macroglobulinemia Who Have Familial Disease Predisposition

The Rituximab and IVIG Related IgM Flare In Waldenstrom's Macroglobulinemia Is Associated with Monocytic Activation of Fcgriia Signaling, and Triggering of IL-6 Release by the PI3K/AKT and MAPK Pathways

The Anti-CD20 Monoclonal Antibody GA101 Displays More Robust Anti-Tumor Activity Versus Rituximab In Waldenstrom's Macroglobulinemia (WM)

Bendamustine-Based Therapy Is Highly Active In Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

Associated Malignancies Among Patients and Kin with Waldenstrom's Macroglobulinemia

Comprehensive Assessment of Cytokines and Chemokines In Patients with Waldenstrom's Macroglobulinemia Reveals a Distinct Profile with Pathobiological and Clinical Relevance

IgA and IgG Hypogammaglobulinemia Does Not Predict for Recurrent Infection Risk and Persists Despite Therapeutic Response in Patients with Waldentrom's Macroglobulinemia.

Genome Wide Association Studies of Familial Waldenstrom's Macroglobulinemia (WM) Reveals a Loss of GSTM1 Is Common in Families with a History of B-Cell Disorders but Not in Those with a History Specific for WM.

The Inhibitory Receptor FcgRIIB Is Overexpressed, and Its Ligation by Anti- FcgRIIB Antibodies Suppresses IgM Production and Induces Apoptosis in Waldenstrom's Macroglobulinemia.

Maintenance Rituximab Is Associated with Improved Progression Free and Overall Survival in Waldenstrom's Macroglobulinemia.

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

Progression Free Survival Is Predicated by Categorical Response, and Supports the Attainment of VGPR/CR as An Objective for Long Term Disease Control in Waldenstrom's Macroglobulinemia.

Gene Expression Profiling Distinguishes Waldenstrom's Macroglobulinemia Patients Presenting with Familial Disease, Advanced IPSS Prognostic Score, and Previous Treatment with Rituximab.

The IgM Flare Following Rituximab and IVIG Administration in Waldenstrom's Macroglobulinemia Is Related to IL-6 Production by Bystander Immune Cells, Possibly through Stimulation of the Fcgriia Receptor.

Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia.

Cholesterol Regulation and Statin Therapy in Patients with Waldenstrom's Macroglobulinemia.

Patients with Waldenstrom's Macroglobulinemia Are Often Hypoferremic That Is Refractory to Oral Iron Repletion and Responsive to Parental Iron Infusions, and Demonstrate Elevated Levels of Hepcidin.

Polymorphisms of FcγRIIA, FcγRIIB, and FcγRIIIA and Therapeutic Response to Rituximab Combination Therapy in Patients with Waldenstrom's Macroglobulinemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only